Videotaped Proceedings from Symposium: Eliminating Legal, Regulatory, and Economic Barriers to Biodefense Vaccine Development. June 9, 2004 Baltimore, Maryland

• Is Bioshield the Answer?, Philip Russell, Special Advisor on Vaccine Development and Production, Office of Public Health Preparedness, U.S. Department of Health and Human Services
  
  
• The Role of FDA, Margaret O'K. Glavin, Assistant Commissioner for Counter Terrorism, U.S. Food and Drug Administration
  
  
• The Need for Regulatory Flexibility in the Face of Emergent Threats, Gail Javitt, Policy Analyst, Genetics and Public Policy Center, Phoebe R. Berman Bioethics Institute, Johns Hopkins University
  
  
• The Role of Intellectual Property Policy, Cynthia Ho, Associate Professor, Loyola University School of Law, Chicago, IL
  
  
• The NIH Biodefense Research Agenda, Ernest T. Takafuji, Assistant Director for Biodefense Research, National Institute of Allergy and Infectious Diseases (NIAID)
  
  
• Issues of Consent and Standard of Care in the Administration of Vaccines in Response to a Bioterrorist Threat, Wendy Parmet, Professor of Law, Northeastern University School of Law, Boston, MA
  
  
• Compensation and Liability for Vaccines: The Special Case of Vaccines for Bioterrorism Agents, Edward Richards, Harvey A. Peltier Endowed Professor and Director, Program in Law, Science and Public Health, Louisiana State University, Baton Rouge, LA
  
  
• Liability Issues Associated with Vaccine Development and Distribution, William C. Bertrand, Jr., Vice-President, General Counsel, and Corporate Compliance Officer, MedImmune